Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02521545 | Single-Dose Study of a New Formulation of BIIB061 | PHASE1 | COMPLETED | 8 | — | — | Jul 1, 2015 | Aug 1, 2015 | Sep 7, 2015 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| BIIB061 | EXPERIMENTAL | Single oral dose of 30 mg BIIB061 of the new formulation |
| Name | Type | Description |
|---|---|---|
| BIIB061 | DRUG | Capsule |
Key Inclusion Criteria: * Males and postmenopausal (defined as no menses for 12 months and confirmed by follicle-stimulating hormone \[FSH\] levels determined at screening to be in the postmenopausal range) or surgically sterile females. * All male subjects must practice effective contraception dur...